The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
17:35

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

COVID-19 Coagulopathy: What Is Virchow’s Triad? What Are the VTE Rates in COVID-19? Is Thromboprophylaxis With LMWH Recommended?

FEATURING Penelope Harris
  • 15 views
  • March 9, 2021
18:31

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

COVID-19 Therapeutics: Remdesivir/Bamlanivimab/Casirivimab+Imdevimab - What Is the Most Effective Drug? Should We Still Consider TKIs for Hem Patients?

FEATURING Kelsey Konrardy
  • 11 views
  • March 9, 2021
15:40

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

COVID-19 & Hematologic Malignancies: What Is the Mortality Estimate Per Malignancy? Are Allo-HSCT Patients at Higher Risk? Is Vaccine Recommended for All Disease Groups?

FEATURING Jordan Leal
  • 23 views
  • March 9, 2021
19:48

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

2021 Updates on Thrombosis: VTE & Recurrence, Use of DOACs in GI/GU Cancer-Associated Thrombosis, Thrombotic Microangiopathy and HIT, AB023 in ESRD

FEATURING Konstantine Halkidis
  • 16 views
  • March 8, 2021
17:38

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

CAR-T & Experimental Therapeutics for AML: Is Allo-SCT the Only Chance for Long-Term Cure? What Are the Challenges of Immune-Based Therapy? BiTES, BiKEs and TriKEs

FEATURING Tara Lin
  • 11 views
  • March 8, 2021
15:46

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

SCT for MDS: Do Older Patients With Advanced MDS Benefit From Allo-HCT? Are There 3-Year OS Improvements? Are Younger HLA-Matched Unrelated Donors Associated With Superior DFS vs. Older Donors?

FEATURING Anurag K. Singh
  • 109 views
  • March 8, 2021
05:21

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

HCT in MF: Is OS Better With Upfront JAKi vs. HCT? What Are the Outcomes for Allo-HSCT With Post-Transplantation Cyclophosphamide?

FEATURING Anurag K. Singh
  • 76 views
  • March 8, 2021
09:23

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on HCT for AML: Are We Starting to Refer AML Patients Earlier in CR1? Can PTCy Overcome HLA Barriers in Haplo-Identical HCT?

FEATURING Muhammad Umair Mushtaq
  • 29 views
  • March 8, 2021
  • 2
07:01

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

Allogeneic Transplantation & AML Outcomes: What Is the Role of HSCT in Patients Treated With Upfront VEN/AZA? Is It Safe to Add Ven to FluBu2 Reduced Intensity Conditioning Chemo?

FEATURING Muhammad Umair Mushtaq
  • 4 views
  • March 8, 2021
08:38

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on Myelofibrosis: What Are the Outcomes After Ruxolitinib Discontinuation? What Is the Additional Benefit of Parsaclisib & Ruxolitinib? Does LSD1 Improve Symptoms and OS?

FEATURING Abdulraheem Yacoub
  • 117 views
  • March 8, 2021
  • 1
07:44

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on CML Management: Does the TKI Choice Affect Survival? Are There Any Superiorities Between Dasatinib & Nilotinib? What Is Efficacy/Safety, and MMR Rate of a First-in-Class Stamp Inhibitor vs. Bosutinib?

FEATURING Abdulraheem Yacoub
  • 84 views
  • March 5, 2021
09:26

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

1L Therapy for Ph- B-ALL: What Is Blinatumomab MRD Response & RFS? Is There Improved CR/CRI of Inotuzumab + Chemo?

FEATURING Ken Byrd
  • 11 views
  • March 5, 2021
09:20

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

1L Therapy for T-ALL: What Are the AALL0434 vs. AALL1231 EFS/OS Outcomes? Is There More Gr4-5 Infectious Toxicity in AALL1231?

FEATURING Ken Byrd
  • 74 views
  • March 5, 2021
06:36

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on Intensive Induction for AML: What Is the 5-Year Follow-Up OS Data With CPX-351? Which Agents Are Being Studied in Combination With Intensive Chemo?

FEATURING Heather Male
  • 142 views
  • March 5, 2021
  • 1
11:45

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on Moderate-Intensity Chemo for AML: What Are the Remission Rates & OS of AZA/VEN, and LDAC/VEN? Does OS Improve With VEN + Decitabine for TP53 Mutation in AML, and What Are the New Potential Agents?

FEATURING Heather Male
  • 6 views
  • March 5, 2021
11:54

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on MDS Management: What Are the Outcomes of Venetoclax for Higher Risk MDS? Can We Expect to See Venetoclax + AZA as a New SoC?

FEATURING Barry Skikne
  • 157 views
  • March 5, 2021
08:01

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

TP53 Mutations in MDS: Is Combination of Eprenetapopt + AZA Well-Tolerated in Patients With TP53-Mutant MDS & Oligoblastic AML? What Are the Rates of Clinical Response & Molecular Remissions?

FEATURING Barry Skikne
  • 111 views
  • March 5, 2021
  • 1
14:31

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on Higher-Risk MDS: Efficacy/Safety of Pevonedistat + Azacitidine vs. Azacitidine Alone

FEATURING Barry Skikne
  • 111 views
  • March 5, 2021
  • 1